Afinion gathers momentum as Axis-Shield moves into profitability for the first time
This article was originally published in Clinica
Axis-Shield has enlisted long-time partner Abbott Labs as exclusive US distributor of Afinion, its multi-test point-of-care (POC) analyser. The Anglo-Norwegian company received US FDA clearance for its system and HbA1c diabetes test - the first test approved for use on the analyser - in July this year (see Clinica No 1168, p 22).
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.